CNS Pharmaceuticals, Inc. (CNSP) earnings
CNSP earnings moved a median of +0.15% by the close. Quarterly and annual CNSP reports and results, each read against the price at its own news timestamp. Back to the CNSP overview →
23 measured CNSP earnings events.
Where these CNSP earnings landedvs 23 measured CNSP earnings reactions
| Middle 50% of CNSP earnings reactions | -8.43% to +6.71% |
|---|---|
| Median reaction (to close) | +0.15% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 CNSP earnings events with a measured close landed between -8.43% and +6.71%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation | Press release | +0.00% | -4.02% | |
| Form 10-Q CNS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -4.02% | |
| CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress | Press release | +1.32% | -5.47% | |
| Form 10-Q CNS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +1.32% | -5.47% | |
| Form 10-K/A CNS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +0.89% | +2.72% | |
| Form 10-K CNS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -7.84% | -15.10% | |
| CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | +0.15% | |
| Form 10-Q CNS Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +0.15% | |
| CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.00% | -19.33% | |
| Form 10-Q CNS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -19.33% | |
| CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -2.48% | +5.79% | |
| Form 10-Q CNS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | -2.48% | +5.79% | |
| Form 10-K/A CNS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -2.75% | -2.75% | |
| Form 10-K CNS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | +8.06% | +2.38% | |
| CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results | Press release | -2.95% | -11.38% | |
| Form 10-Q CNS Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | -2.95% | -11.38% | |
| CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results | Press release | +3.66% | +7.63% | |
| Form 10-Q CNS Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | +3.66% | +7.63% | |
| CNS Pharmaceuticals Reports First Quarter 2024 Financial Results | Press release | +4.11% | +17.07% | |
| Form 10-Q CNS Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +4.11% | +17.07% | |
| Form 10-K CNS Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -1.25% | -14.58% | |
| CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End | Press release | +0.00% | +10.35% | |
| Form 10-Q CNS Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +10.35% |
Keep exploring
More CNSP: analyst actions → · SEC filings → · CNSP overview →